8-K: Coya Therapeutics Expands ALS Trial, Delays FTD Study

Coya Therapeutics announced the initiation of an open-label extension for its Phase 2/3 ALSTARS trial in ALS and a revised timeline for its FTD trial.

Summary

• Coya Therapeutics is initiating an open-label extension (OLE) for its Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS).
• This OLE is in response to requests from investigators and participants and will allow those who complete the 48-week treatment to continue receiving COYA 302.
• The OLE is expected to begin in November 2026 as the first cohort finishes the 48-week period.
• Resources will be prioritized for the ongoing ALS trial, leading to a delay in the Phase 2 trial for frontotemporal dementia (FTD), now expected in 2027 instead of the second half of 2026.
• The company's cash runway guidance remains unchanged, with operations funded into the second half of 2027, beyond the anticipated ALSTARS topline data.
• The ALSTARS trial involves approximately 120 subjects randomized to two dosing regimens of COYA 302 or placebo over a 24-week period, followed by an extension phase.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic development, with the initiation of an open-label extension being a positive sign of investigator and patient interest, though the delay in the FTD trial introduces a note of caution.

Positives

• Initiation of an open-label extension for the ALSTARS trial, indicating continued interest and potential benefit from COYA 302.
• The OLE will allow for the collection of longer-term efficacy and safety data for COYA 302 in ALS patients.
• Company cash runway guidance remains unchanged, with sufficient funds to operate into the second half of 2027, extending beyond the expected ALSTARS topline data readout.

Negatives

• The planned initiation of the Phase 2 clinical trial for COYA 302 in frontotemporal dementia (FTD) is delayed from the second half of 2026 to 2027.

Risks

• The actual results of clinical trials may differ from expectations.
• The company's ability to advance its product candidates through development processes.
• The timing and availability of data from clinical trials.
• Potential for unknown risks and uncertainties that could affect actual results.
• Reliance on forward-looking statements which are subject to change.

Future Outlook

The company expects the open-label extension of the ALSTARS trial to begin in November 2026. The Phase 2 trial for FTD is now expected in 2027. Cash runway is projected to extend into the second half of 2027.

Management Comments

• The Company expects the OLE to begin in November 2026 as the first cohort completes the 48-week treatment period.
• Concurrent with the anticipated initiation of the OLE, the Company expects to prioritize resources toward the ongoing clinical development of COYA 302 in ALS and assuring timely completion of important near-term milestones in the ALSTARS Trial.
• With this prioritization, the planned initiation of the Phase 2 clinical trial evaluating COYA 302 in frontotemporal dementia (FTD), previously anticipated in the second half of 2026, is now expected in 2027.
• The Companys cash runway guidance remains unchanged, with existing cash resources expected to fund operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout.

Industry Context

StockSavvy.ai notes that the decision to extend the ALS trial and delay the FTD trial reflects a strategic reallocation of resources, common in biopharmaceutical development where clinical trial progress and data readouts heavily influence future investment and strategic direction. Prioritizing a potentially more advanced or promising indication is a typical, albeit sometimes challenging, decision.

Stakeholder Impact

• Shareholders: May react to the delay in the FTD trial, but the continued ALS trial and unchanged cash runway may provide some reassurance.
• ALS Patients: Benefit from the opportunity to continue treatment through the OLE, allowing for longer-term data collection.
• FTD Patients: Will experience a delay in the potential availability of COYA 302 for their condition.

Next Steps

• Initiate the open-label extension (OLE) of the Phase 2/3 ALSTARS Trial in November 2026.
• Continue clinical development of COYA 302 in ALS.
• Assure timely completion of near-term milestones in the ALSTARS Trial.
• Initiate the Phase 2 clinical trial evaluating COYA 302 in FTD in 2027.

Key Dates

Recommendation

The company is advancing its lead ALS program with an OLE, which is positive. However, the delay in the FTD trial indicates a strategic shift and potential resource constraints that warrant a cautious approach. The unchanged cash runway is a mitigating factor, but the delay introduces uncertainty regarding the FTD indication's timeline.

Keywords

COYA 302, ALS, Amyotrophic Lateral Sclerosis, Clinical Trial, Open-Label Extension, FTD, Frontotemporal Dementia, Phase 2/3 Trial